XENOTECH
A BioIVT Company

Data Sheet
Certificate of Analysis

Fa2N-4 Lot No. 2310144
Immortalized Human Hepatocytes

Produced under license from Corning Incorporated

IFH15 – Cryopreserved cells 1.5 mL vial
IFHP06 – Plated cells 6-well plate
IFHP12 – Plated cells 12-well plate
IFHP24 – Plated cells 24-well plates
IFHP48 – Plated cells 48-well plates
IFHP96 – Plated cells 96-well plates

Enzyme	Prototypical Inducer	Marker Substrate Reaction	Fold Induction
CYP1A2	Omeprazole (60 µM)	Phenacetin O-dealkylation	11.45
CYP2B6	Phenobarbital (750 µM)	Bupropion hydroxylation	1.08
CYP2C9	Rifampin (40 µM)	Diclofenac 4'-hydroxylation	3.31
CYP3A4/5	Rifampin (40 µM)	Midazolam 1'-hydroxylation	1.98
CYP3A4/5	Rifampin (40 µM)	Atorvastatin hydroxylation	2.82

Fa2N-4 immortalized hepatocytes were plated in 24-well plates at 0.33 x 10^6 cells per well on Day 0 and cultured in MFE Support Medium F containing Supplement A on days 1-3. Cells were then treated with inducers (in MFE Support Medium F containing Supplement A) once daily for 3 consecutive days. Substrate incubations were performed for 15 minutes to 6 hours. CYP activity was measured under conditions where the metabolite formation was proportional to incubation time. Samples were analyzed by LC/MS/MS. All substrate concentrations were at 100 µM, except Atorvastatin which was at 250 µM.

Cell Line Information

The Fa2N-4 cell line was prepared by immortalizing hepatocytes from a 12 year-old Caucasian female donor with the SV40 large T antigen. The donor tested negative for CMV, HIV, HBV, and HCV.

Store in liquid nitrogen, vapor phase

CAUTION: This sample should be considered as a potential biohazard and universal precautions should be followed. Intended for *in vitro* use only.

This data sheet serves as a Certificate of Analysis and has been approved by Stephanie Helmstetter, Assistant Director.
Signature and Date: Stephanie Helmstetter 22 June 2023